Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB01319_DB01558_nanopub.RAEKzYjVTxFAX--Ugu6lIuq0HjegDq7FokraS44Yt0at0#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB01319_DB01558 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB01319_DB01558 label "DDI between Fosamprenavir and Bromazepam - Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if fosamprenavir is initiated, discontinued or dose changed. Dosage adjustments may be required. [drugbank_resource:DB01319_DB01558]" assertion.
- drugbank_resource:DB01319_DB01558 identifier "drugbank_resource:DB01319_DB01558" assertion.
- drugbank_resource:DB01319_DB01558 title "DDI between Fosamprenavir and Bromazepam - Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if fosamprenavir is initiated, discontinued or dose changed. Dosage adjustments may be required." assertion.
- drugbank:DB01319 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01319_DB01558 assertion.
- drugbank:DB01558 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01319_DB01558 assertion.